The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

RALEIGH, N.C. (January 13, 2025) – The first group of apprentices has officially signed on with Amgen in a unique program that will prepare a skilled workforce for the biopharmaceutical leader's ...

The latest trading session saw Amgen (AMGN) ending at $267.10, denoting a -1.14% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.12% for the ...

A biotech stock index slid by almost 3%. Amgen is one of those would-be competitors and, at the JPM meeting, executives defended recent trial results for the company’s rival weight loss drug.

Executives at Amgen made the case for MariTide’s differentiation, while Merck’s CEO contended that Keytruda’s coming loss of exclusivity can be managed. SAN FRANCISCO — For any hopes the dealmaking ...

Amgen is best known for its success in the biosimilar market. Image credit: Shutterstock / Michael Vi. Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be ...